Annie Lamont warns on China, exposing the cost of FDA red tape
By Grant Colby · Reporting from Amarillo ·
On the Sourcery podcast, investor Annie Lamont revealed American pharma sends 50 percent of research dollars to China, proving Washington must slash FDA red tape to secure domestic drug innovation.
The most alarming revelation from veteran venture capitalist Annie Lamont on the latest episode of the Sourcery podcast had nothing to do with Silicon Valley valuations. It had everything to do with American national security. Speaking with host Molly at the New York Stock Exchange, the Oak HC/FT co-founder revealed that American pharmaceutical companies have directed 50 percent of their external research dollars to China—a massive shift from five years ago. On Sourcery, Lamont argued that China's rapid rise in life sciences represents an existential threat to the United States. It risks both commercial leadership and domestic drug security.
The China Vulnerability in American Pharma
Lamont’s warning ought to wake up every lawmaker in Washington. As someone who flew C-130 transports in Desert Storm and built a logistics business from the ground up, I know supply chain dependence is strategic surrender. We saw during the pandemic what happens when essential active pharmaceutical ingredients are made overseas by a foreign adversary. Allowing half of our drug research and development capital to migrate to Chinese laboratories forfeits critical intellectual property and weakens American deterrence.
Lamont contends that the antidote lies in leveraging advanced technology like artificial intelligence and computational biology at home. That must be paired with a wholesale overhaul of the Food and Drug Administration. Venture-backed firms like Chai Discovery are already using specialized AI models to accelerate drug design, compressing timelines that used to take years into days. But technology alone cannot close the gap if regulatory agencies continue to drag their feet.
To be sure, globalists and biotech executives contend that outsourcing early-stage research to cheaper Chinese facilities stretches venture dollars further, allowing companies to run more clinical experiments per dollar spent. They argue that scientific progress is inherently global and that shutting off overseas partnerships would slow down life-saving discoveries for American patients.
That argument misses the forest for the trees. Cost efficiency cannot take precedence over sovereign defense. A country that cannot research and manufacture its own medicine is at the mercy of the regime hosting its laboratories.
Slashing Bureaucracy to Rebuild Main Street Enterprise
The root cause of capital flight isn't a lack of American talent—it's federal red tape. Lamont noted on the show that administrative overhead consumes 25 to 30 percent of total healthcare spending in the United States. That is a crushing tax on private enterprise. When regulatory compliance, paperwork, and bureaucratic friction consume nearly a third of an industry's budget, capital naturally flows to jurisdictions where work gets done faster.
Market-driven solutions are already showing what happens when technology bypasses administrative bloat. Lamont highlighted portfolio companies like Devoted Health, which used custom technology and AI while slashing operating ratios. She also pointed to Augur, where Oak HC/FT committed $100 million upfront under former Amazon executive Dave Clark to orchestrate real-time supply chain operations. When private capital is allowed to build without heavy-handed intervention, it delivers results.
The historical record is uncompromising: heavy regulation at home does not eliminate risk. It simply exports industries to foreign rivals who operate under no such burdens. If Washington wants to keep critical biopharmaceutical research inside American borders, it must aggressively streamline the FDA, cut clinical trial paperwork, and let free enterprise work.
National strength rests on two pillars: deterrence abroad and economic freedom at home. Funding our chief economic competitor's scientific apparatus while suffocating domestic firms in administrative overhead threatens both. American leadership in life sciences will not be preserved through federal subsidies. It demands cutting Washington red tape and unleashing private innovation before our drug supply becomes another foreign leverage point.